### ðŸ«€ Cardiology: Valvular Atrial Fibrillation Anticoagulation

#### âœ… True Statements
1. **Warfarin**, a vitaminÂ K antagonist, is indicated for systemic anticoagulation in **all** patients with stageâ€¯B, C, orâ€¯D rheumatic **mitral stenosis** who have concomitant **atrial fibrillation** (valvular atrial fibrillation).  
2. Approximately **50â€¯%** of patients with rheumatic mitral stenosis develop atrial fibrillation, and **without anticoagulation their risk of systemic thromboembolism is aboutâ€¯20â€¯%â€“25â€¯%**.  
3. Anticoagulation with **warfarin** is recommended for patients with rheumatic mitral stenosis who have a **history of left atrial thrombus** or prior **systemic embolic events**.  
4. The **CHAâ‚‚DSâ‚‚â€‘VASc score** is **not used** to guide anticoagulation decisions in patients with rheumatic mitral stenosis and atrial fibrillation.  
5. **Direct oral anticoagulants (DOACs)**â€”including **dabigatran**, **rivaroxaban**, **apixaban**, and **edoxaban**â€”are **not approved** for use in **valvular atrial fibrillation** and may be associated with harm in this population.  
6. **Antiplatelet therapy** (alone or dual) is **inferior to vitaminÂ K antagonists** for stroke prevention in atrial fibrillation and should **not** be used in patients with rheumatic mitral stenosis and atrial fibrillation **unless an additional indication (e.g., coronary artery disease) is present**.  

#### ðŸ’¬ Extra
1. Guidelineâ€‘directed therapy targets an **international normalized ratio (INR) ofâ€¯2.0â€“3.0** for warfarin in rheumatic mitral stenosis with atrial fibrillation.  
2. This high embolic risk exists **independent of traditional strokeâ€‘risk scores**.  
3. **Transesophageal echocardiography (TEE)** is preferred for detecting left atrial thrombus before intervention.  
4. Strokeâ€‘risk scores such as **CHAâ‚‚DSâ‚‚â€‘VASc** were validated in **nonvalvular** atrial fibrillation and have limited applicability in rheumatic mitral stenosis.  
5. The randomized **INVICTUSâ€“Rheumatic Heart Disease** trial demonstrated a higher composite of cardiovascular events with **rivaroxaban** compared with warfarin in rheumatic valvular atrial fibrillation.  
6. Combination therapy with warfarinâ€¯+â€¯aspirin is reserved for circumstances such as **recent coronary stenting** when bleeding risk is acceptable.  

#### ðŸ”· Tags
#Cardiology #AmbulatoryCare #ValvularHeartDisease #MitralStenosis #AtrialFibrillation #Anticoagulation #Warfarin

#### ðŸ“™ Reference
Joglarâ€¯JA, Chungâ€¯MK, Armbrusterâ€¯AL, etâ€¯al. 2023â€¯ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation. *Circulation*.â€¯2024;149:e1â€‘e156. PMID:â€¯38033089 doi:10.1161/CIR.0000000000001193

#### ðŸ†” Question ID
CVQQQ24005

#### ðŸ•’ Last Updated
Februaryâ€¯2025

---

#### ðŸ“– Related Text
MKSAPâ€¯19: Cardiovascular Medicineâ€¯â€”â€¯Mitral Stenosis, Management

---

### ðŸ“˜ Related Text Derivations

#### âœ… True Statements
1. **Percutaneous balloon mitral commissurotomy (PBMC)** is the **procedure of choice** for severe rheumatic mitral stenosis when the valve is **pliable and not heavily calcified**.  
2. **PBMC** is **indicated** in **symptomatic** patients with severe rheumatic mitral stenosis and **favorable valve morphology**.  
3. **PBMC** is **reasonable** in **asymptomatic** patients with severe rheumatic mitral stenosis who have a **pulmonary artery systolic pressure >â€¯50â€¯mmâ€¯Hg**.  
4. **PBMC** should **not** be performed when **transesophageal echocardiography (TEE)** reveals **left atrial thrombus** or when moderateâ€‘toâ€‘severe **mitral regurgitation** is present.  
5. In appropriately selected patients, **PBMC** achieves a **procedural success rate â‰ˆâ€¯95â€¯%** with **complication rates <â€¯5â€¯%**.  
6. **Surgical mitral valve surgery** (repair or replacement) is indicated for patients with severe mitral stenosis, **New York Heart Association (NYHA) classâ€¯III orâ€¯IV symptoms**, and **unfavorable valve anatomy**, or for **asymptomatic** patients who require **concomitant cardiac surgery** for another indication.  
7. Symptomatic control in rheumatic mitral stenosis can be achieved with **negative chronotropic agents**, **diuretics**, and **longâ€‘acting nitrates** in patients who are **not candidates** for interventional or surgical therapy.  
8. All patients with rheumatic mitral stenosis and atrial fibrillation should receive **warfarin anticoagulation with a target INR ofâ€¯2.0â€“3.0**, because **direct oral anticoagulants are not recommended** in this setting.  

#### ðŸ’¬ Extra
1. A **Wilkins echocardiographic scoreâ€¯â‰¤â€¯8** typically defines favorable valve morphology for PBMC.  
2. Severe rheumatic mitral stenosis is generally defined as a **mitral valve area â‰¤â€¯1.5â€¯cmÂ²**.  
3. Elevated pulmonary artery pressure reflects **hemodynamic burden** despite lack of symptoms.  
4. Embolization risk during PBMC is increased by left atrial thrombus or significant mitral regurgitation.  
5. Major complications of PBMC include **severe mitral regurgitation** and **cardiac tamponade**.  
6. **Calcification** and **subvalvular fusion** lower the likelihood of successful commissurotomy.  
7. Rateâ€‘slowing agents reduce transmitral gradient by prolonging diastolic filling time, thereby **reducing left atrial pressure and symptoms**.  
8. The randomized **INVICTUS trial** found higher rates of **stroke, systemic embolism, myocardial infarction, or vascular death** with **rivaroxaban** compared with warfarin in rheumatic mitral stenosis with atrial fibrillation.  

#### ðŸ”· Tags
#ValvularHeartDisease #MitralStenosis #PercutaneousBalloonMitralCommissurotomy #AtrialFibrillation #Anticoagulation #Cardiology
